Developing Microbial Therapy for MASLD: From Mechanism to Clinical Validation

NCT07488975

Status	RECRUITING
Phase	Phase 1
Sponsor	Leeuwenhoek Laboratories Co. Ltd.
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (1)

- Fibroscan CAP g 260db/m

Exclusion (6)

- A. Pregnant women or women who are breastfeeding. B. Use of probiotics and prebiotic-related products (including yogurt, yogurt, Yakult, etc.) within 14 days before the screening visit.
- C. Patients who have used antibiotics (except skin lotions) or antifungal drugs within 30 days before the screening visit.
- D. Use of glucagon-like peptide-1 receptor agonists (GLP1-RAs) within six months prior to the screening visit.
- E. Use of drugs that may affect the evaluation index within 14 days before the screening visit, during the screening visit, or during the planned trial period, such as steroids, immunosuppressants, or anti-inflammatory drugs, or drugs containing ingredients for treating hepatitis or affecting fat metabolism, including HMG-CoA reductase inhibitors (statins), fibrates, silymarin, thiazolidinediones, metformin, cholestyramine, ezetimibe, orlistat, and sodium-glucose transporter type 2 inhibitors (SGLT2i). This restriction does not apply if the above-mentioned drugs have been used continuously for more than six months and the dosage is not changed during the trial.
- F. Those who have had severe gastrointestinal infection diarrhea symptoms within 14 days before the screening visit (more than three watery stools in 24 hours).

... and 1 more (see full listing online)

Locations (1 total)

National Taiwan University Hospital, Taipei, Taiwan